Bifogade filer
Kurs & Likviditet
Kalender
Tid* | ||
2025-05-20 | 09:00 | Kvartalsrapport 2025-Q1 |
2025-05-20 | - | Årsstämma |
2025-02-25 | 08:00 | Bokslutskommuniké 2024 |
2024-11-19 | 09:00 | Kvartalsrapport 2024-Q3 |
2024-08-27 | - | Kvartalsrapport 2024-Q2 |
2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2024-05-21 | - | Årsstämma |
2024-05-21 | - | Kvartalsrapport 2024-Q1 |
2024-02-20 | - | Extra Bolagsstämma 2024 |
2024-02-20 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-22 | - | Kvartalsrapport 2023-Q2 |
2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2023-05-23 | - | Årsstämma |
2023-05-23 | - | Kvartalsrapport 2023-Q1 |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-11-16 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-05-10 | - | Årsstämma |
2022-03-29 | - | Extra Bolagsstämma 2022 |
2022-02-22 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-07-13 | - | Kvartalsrapport 2021-Q2 |
2021-05-20 | - | Split SYNT 1:10 |
2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
2020-07-14 | - | Kvartalsrapport 2020-Q2 |
2020-05-05 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-12 | - | Kvartalsrapport 2019-Q3 |
2019-07-14 | - | Kvartalsrapport 2019-Q2 |
2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
2019-04-29 | - | Kvartalsrapport 2019-Q1 |
2019-04-29 | - | Årsstämma |
2019-02-27 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-04-25 | - | Årsstämma |
2018-02-21 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2017-04-25 | - | Årsstämma |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-02-15 | - | Bokslutskommuniké 2016 |
2016-10-28 | - | Kvartalsrapport 2016-Q3 |
2016-08-26 | - | Kvartalsrapport 2016-Q2 |
2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2016-04-26 | - | Årsstämma |
2016-04-26 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-10-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-04-13 | - | Årsstämma |
2015-04-13 | - | Kvartalsrapport 2015-Q1 |
2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2015-02-13 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-09-26 | - | Extra Bolagsstämma 2014 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States.
[image]
SyntheticMR is proud to announce that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This milestone marks a significant advancement in quantitative MRI technology, offering unprecedented resolution and accuracy in brain imaging.
"We are thrilled to receive 510(k) clearance for SyMRI 3D," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, revolutionizing the landscape of medical diagnostics and offering new possibilities for diagnosis and treatment."
SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.
"Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," says Jared Dixon, President of SyntheticMR U.S Inc.
With this clearance, SyntheticMR reaffirms its commitment to advancing medical imaging technology and providing clinicians with innovative tools to enhance patient care. SyMRI 3D opens up new possibilities for precise diagnosis, treatment planning, and monitoring, ultimately improving patient outcomes.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-03-2024 11:01 CET.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com (ulrik.harrysson@syntheticmr.com)or Jared Dixon, President SyntheticMR U.S Inc. at +1 (859) 2401965 or jared.dixon@syntheticmr.com